|
1.
Exjade (deferasirox) File Format: PDF/Adobe Acrobat - View as HTML The recommended initial daily dose of Exjade, 20 mg/kg body weight, may be adjusted for the patient's transfusion rate and the goal of therapy. Exjade at ... 2.
Sickle Cell Disease and Iron Overload File Format: PDF/Adobe Acrobat - View as HTML Long‐Term use of Exjade® (deferasirox) in Patients with. Sickle Cell Disease and Transfusional Iron Overload. 3.5‐Year Efficacy and Safety Results ... 3.
Novartis Oncology's Cancer Treatments : Exjade, Femara, Glivec ... Get informed on Novartis Oncology's products (with related Websites links) for cancer treatment: Exjade, Femara, Glivec, Sandostatin, Tasigna, Zometa. 4.
Novartis Oncology's Cancer Treatments : Exjade, Femara, Glivec ... Get informed on Novartis Oncology's products (with related Websites links) for cancer treatment: Exjade, Femara, Glivec, Sandostatin, Tasigna, Zometa. 5.
Sickle Cell Disease and Iron Overload File Format: PDF/Adobe Acrobat - View as HTML Long‐Term use of Exjade® (deferasirox) in Patients with. Sickle Cell Disease and Transfusional Iron Overload. 3.5‐Year Efficacy and Safety Results ... 6.
Exjade (deferasirox) File Format: PDF/Adobe Acrobat - View as HTML Exjade is administered as a drink after the tablets are dispersed in a glass of orange juice, apple juice or water. Exjade dosing can be tailored to each ... 7.
Novartis Oncology's Cancer Treatments : Exjade, Femara, Glivec ... Get informed on Novartis Oncology's products (with related Websites links) for cancer treatment: Exjade, Femara, Glivec, Sandostatin, Tasigna, Zometa. 8.
Glivec (imatinib) -- Fact Sheet File Format: PDF/Adobe Acrobat - View as HTML Within-Trial Resource Utilisation and Costs of Patients. Randomised to Treatment with Imatinib (STI571) Versus Interferon-Alpha (IFN-a) Combined with ... 9.
Message from David Epstein, CEO and President of Novartis Oncology To learn about Novartis Oncology's vision and values read the message of David Epstein, CEO & President of Novartis Oncology. 10.
Novartis Oncology - A Message from David Epstein, CEO and President Dr Alessandro Riva joined Novartis Oncology in January 2005 as Global Head of Novartis Oncology Development. Working closely with research and experimental ... |
